Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops

Moriche-Carretero, Manuel; Revilla-Amores, R; Díaz-Valle, D.; Morales-Fernández, Laura; Gómez-de-Liaño, R.

doi:10.1016/j.jfo.2021.07.005

Cited by 20 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A 2-year RCT study in Spain revealed that 0.01% atropine eye drops were effective in slowing the progression of myopia based on the changes in both SE and AL [ 23 ]. At the 2 years follow-up visit, SE changed by −0.51 (SD 0.39) D in the atropine treatment group vs. −0.76 (SD 0.37) D in the control group, ( p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

“…Nevertheless, some study subjects did not respond to treatment or treatment effect was limited to 1.5 years. About 20% of children were non-responders in the study by Moriche-Carretero et al (SE increase of >1 D/2 years) [ 23 ], and 36% in the study by Polling et al [ 21 ]. In the latter report, an atropine eye drops’ dose as high as 1% did not diminish myopia progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

Simonaviciute

Grzybowski

Lança

et al. 2023

JCM

View full text Add to dashboard Cite

Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering risk–benefit ratio and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability to atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients complains and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving less side effects compared to 0.5% concentration.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

Simonaviciute

Grzybowski

Lança

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Die Mehrheit der publizierten randomisierten kontrollierten Studien zur Sicherheit und Wirkung von niedrig dosiertem Atropin stammen bis auf wenige Ausnahmen [ 26 ] aus Asien [ 3 ]. Beispielsweise sind für große Studien aus Australien und England erst die Protokolle bzw.…”

Section: Interventionen Zur Progressionsminderungunclassified

Empfehlungen bei progredienter Myopie im Kindes- und Jugendalter. Stellungnahme von DOG, BVA und der Bielschowsky Gesellschaft für Schielforschung und Neuroophthalmologie

Lagrèze¹,

Bertram²,

Ehrt³

et al. 2022

Ophthalmologie

View full text Add to dashboard Cite

Seit der letzten und gleichzeitig ersten Stellungnahme der deutschen ophthalmologischen Fachgesellschaften zu den Möglichkeiten der Minderung von Myopieprogression im Kindes- und Jugendalter haben sich in der klinischen Forschung viele neue Details und Aspekte ergeben. Die nun vorliegende, zweite Stellungnahme aktualisiert das bisherige Dokuments und konkretisiert die Empfehlungen sowohl zum Seh- und Leseverhalten als auch zu den pharmakologischen und optischen Therapieoptionen, die in der Zwischenzeit sowohl verfeinert als auch neu entwickelt wurden.

show abstract

“… 20 Taken together, these results support the notion that highly diluted atropine eye drops reliably attenuate myopia progression while minimising side effects. 13 While the use of highly diluted atropine in Asian populations has been demonstrated in blinded, well-designed trials, 28–30 only few randomised trials have been completed in Caucasian populations. 28 29 Therefore, the cumulative evidence in Caucasian populations is not yet strong enough to prove the efficacy of atropine in these populations.…”

Section: Introductionmentioning

confidence: 99%

“… 13 While the use of highly diluted atropine in Asian populations has been demonstrated in blinded, well-designed trials, 28–30 only few randomised trials have been completed in Caucasian populations. 28 29 Therefore, the cumulative evidence in Caucasian populations is not yet strong enough to prove the efficacy of atropine in these populations. This led to a number of randomised, controlled trials currently being conducted in Caucasian populations.…”

Section: Introductionmentioning

confidence: 99%

Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms

et al. 2023

View full text Add to dashboard Cite

IntroductionMyopia is a major cause of degenerative eye disease and increases the risk of secondary visual impairment. Mitigating its progression therefore has great potential of clinically relevant benefit as shown by using highly diluted atropine eye drops in children of Asian origin. However, limited evidence is available regarding the efficacy and safety of low-dose atropine therapy in non-Asian populations. Hence, the Low-dose AtropIne for Myopia Control in Children (AIM) study will test the efficacy and safety of 0.02% atropine vs placebo in a German population.Methods and analysisAIM is a national, multicentre, prospective, randomised, placebo-controlled, double-blind trial with two parallel arms. The primary objective is to assess the efficacy of atropine 0.02% eyedrops for myopia control in children of Caucasian origin. The primary outcome is the change in cycloplegic refraction after 1 year of treatment (D/year). Secondary and tertiary outcome measures comprise the change in axial length (mm/year) in children treated with 0.02% atropine compared with placebo, the myopic progression of participants treated with 0.01% compared with 0.02% atropine (D/year and mm/year), and the safety profile of both 0.02% and 0.01% atropine. Furthermore, the myopic progression 1 year after cessation of therapy with 0.02% atropine will be evaluated. Inclusion criteria are an age of 8–12 years and myopia of −1 D to −6 D with an estimated annual myopia progression of ≥0.5 D. After randomisation, patients will receive either atropine 0.02% (arm A) or placebo eye drops (arm B) in the first year of treatment. In the second year, they will continue to receive atropine 0.02% (arm A) or switch to atropine 0.01% (arm B). In the third year, they will switch to placebo (arm A) or continue with atropine 0.01% (arm B). To achieve a statistical power of 80%, the calculated sample size is 300. The trial has started in October 2021 with a planned recruitment period of 18 months.Ethics and disseminationAIM has been approved by the Central Ethics Committee of the University Medical Center Freiburg (21-1106), local ethics committees of each participating centre and the German Federal Institute for Drugs and Medical Devices (61-3910-4044659). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Results and underlying data from this trial will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberNCT03865160.

show abstract

Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops

Cited by 20 publications

References 22 publications

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

Empfehlungen bei progredienter Myopie im Kindes- und Jugendalter. Stellungnahme von DOG, BVA und der Bielschowsky Gesellschaft für Schielforschung und Neuroophthalmologie

Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms

Contact Info

Product

Resources

About